This SBIR Phase I award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $275,000 to Tectaria Bio LLC to test the feasibility of using engineered cell lines with activated proteasomes to increase the efficiency of biomanufacturing for advanced therapies. The project aims to demonstrate that this technology can enhance protein production in cells commonly used to manufacture gene therapies, biologics, and vaccines. Successful completion of this 10-month project could lead to innovations that lower the costs of producing advanced therapies, making them more accessible to address debilitating diseases like Alzheimer's and cancer. No subawards are planned under this grant.
Generated 3/4/25, 4:31 AM